Survival of patients with glioblastoma multiforme treated by intraoperative high‐activity cobalt 60 endocurietherapy

P. Pradeep Kumar, Roger R. Good, Ernest O. Jones, A. A. Patil, Lyal G. Leibrock, Rodney D. McComb

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

The authors report their initial treatment results in 49 patients with glioblastoma multiforme (GM) who received intraoperative endocurietherapy (ECT) with high‐activity cobalt 60 (60Co) probe. Thirty poor prognosis (unresectable tumor) patients (Group I) with newly diagnosed GM were treated by either biopsy or subtotal excision, followed by 20.00‐Gy single‐fraction 60Co probe ECT, and 60.00‐Gy external‐beam radiation therapy (EXRT) (80.00 Gy total tumor dose). Nineteen patients (Group II) with recurrent, previously resected and externally irradiated GM were retreated with 20.00‐Gy single‐fraction 60Co probe ECT alone. The authors' initial experience with intraoperative ECT of GM is discussed.

Original languageEnglish (US)
Pages (from-to)1409-1413
Number of pages5
JournalCancer
Volume64
Issue number7
DOIs
StatePublished - Oct 1 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survival of patients with glioblastoma multiforme treated by intraoperative high‐activity cobalt 60 endocurietherapy'. Together they form a unique fingerprint.

  • Cite this